10.07.26 -- New USP Guidelines, Standards Address Lentivirus Characterization

Choosing the best sporicide for your cleanroom involves evaluating factors like surface format, contact time, and safety. Examine the criteria to select an effective and robust agent for contamination control.

Stay ahead of FDA QMSR, EU GMP, and AI regulations by adopting continuous audit readiness, ALCOA++ data integrity, and closed-loop workflows for global compliance.

Personalized therapies and advanced technologies are reshaping manufacturing. Explore how intelligent automation can improve flexibility, strengthen data integrity, and accelerate production.

Complex laboratory processes increase regulatory risks. Modern cloud device management safeguards data integrity and provides real-time monitoring across critical lab equipment.

Rapid mycoplasma testing enhances cell and gene therapy safety by reducing turnaround time, minimizing sample needs, and delivering sensitive, reliable contamination detection across diverse matrices.

Evaluate packaging integrity and master wiping techniques to prevent cleanroom contamination. Focus on surface coverage and controlled transfer paths to ensure consistent product safety and quality.

Even well-funded lab informatics environments can leave scientists managing manual handoffs. The real bottleneck often sits between systems, where disconnected workflows slow R&D progress.

Uncover how evolving regulatory pathways and CMC innovation are shaping the future of gene therapy and viral vector production, plus what to consider when selecting a CDMO partner.

Aligning gene-editing programs with updated FDA expectations requires targeted risk assessment strategies. Modern evaluation approaches ensure regulatory compliance and trial safety.

Rising Annex 1 demands are pushing facilities to rethink contamination control. See how RABS retrofits offer a practical path to compliance, combining effective containment and faster implementation.

Gene therapy requires early, rigorous safety planning and command of pediatric and biosafety rules. Early committee engagement reduces delays and strengthens high‑stakes trials.

Preparing for method validation, a biopharma company needed to characterize cIEF charge variants and confirm peak identities for regulatory readiness.

Early decisions on expression systems impact final product quality and costs. Cross-functional team coordination resolves CMC bottlenecks when moving to commercial manufacturing.